V-STRUT
Commercial- Indications
- osteoporosis, bone cancer
Company intelligence / Profile preview
Hyprevention has developed and commercialized implantable medical devices such as Y-STRUT® and V-STRUT®, designed to reinforce bones weakened by osteoporosis or cancer. Y‑STRUT® is approved in Brazil and Israel but not yet FDA-cleared; V‑STRUT received its first FDA 510(k) clearance in 2020. Clinical trials are ongoing for additional indications including traumatology. The STRUTPLASTY® platform combines PEEK polymer implants with PMMA bone cement to prevent or treat fractures.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hyprevention.